Summary
25I-NBF is approximately 6-8 times less potent than 25I-NBOMe but shares a similar qualitative effect profile and comparable safety concerns. Primary activity occurs through potent partial agonism at 5-HT2A and 5-HT2C receptors with bias toward ฮฒ-arrestin 2 signaling; peripheral ฮฑ-adrenergic activity contributes to vasoconstriction and cardiovascular strain. Oral bioavailability is low; sublingual, buccal, or insufflated administration is typically used. Marked vasoconstriction, tachycardia, and hypertension have been reported at doses of 8 mg and above. Fatal intoxications with closely related NBOMe compounds have occurred, often involving polydrug combinations with stimulants or MAOIs.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Sublingual | 10-30 min | 30-60 min | 2-4 hrs | 2-4 hrs | 2-8 hrs |
| Insufflated | 5-15 min | 20-45 min | 2-4 hrs | 2-4 hrs | 2-8 hrs |
| Oral | 30-60 min | 45-90 min | 2-4 hrs | 2-4 hrs | 2-8 hrs |
Tolerance
Build-up
develops rapidly after a single use (serotonergic psychedelic)
Reset
7โ14 days for baseline
Effects
Positive
- Stimulation
- Physical euphoria
Negative
- Increased heart rate
- Vasoconstriction
- Nausea
- Pupil dilation
- Insomnia
- Restlessness
- Sedation
- Spontaneous bodily sensations
Positive
- Euphoria
- Empathy
- Conceptual thinking
- Analysis enhancement
Negative
- Anxiety
- Confusion
- Thought loops
- Memory suppression
- Motor control loss
- Time distortion
Positive
- Colour enhancement
- Bodily control enhancement
- Tactile enhancement
- Color enhancement
- Tracers
- Increased music appreciation
Negative
- Visual patterning
- Closed-eye visuals
- Drifting
- Auditory distortion